使用纵向GWAS模型检测阿尔茨海默病的时间变化的遗传效应
bioRxiv : the preprint server for biology
|October 31, 2023
概括
纵向全基因组关联研究 (GWAS) 确定了对阿尔茨海默病 (AD) 进展具有时间变化的影响的遗传变异. 这些发现揭示了年龄相关的遗传影响对临床损伤和AD中的粉样蛋白积累.
科学领域:
- 遗传学 是一个遗传学.
- 神经科学是一个神经科学.
- 生物统计学 生物统计学
背景情况:
- 阿尔茨海默病 (AD) 的进展涉及复杂的,随时间变化的遗传影响.
- 纵向全基因组关联研究 (GWAS) 可以识别具有动态效应的遗传位置.
- 了解这些随时间变化的效应对于揭示AD病变的发病过程至关重要.
研究的目的:
- 在AD中使用纵向GWAS识别具有时间或年龄依赖作用的单核酸多态 (SNP).
- 调查对临床损伤和随着时间的推移而粉样蛋白积累的动态遗传影响.
- 通过结合时间变化的系数来增强AD-GWAS的统计能力.
主要方法:
- 利用了1877名阿尔茨海默氏症神经成像数据倡议 (ADNI) 参与者的纵向数据.
- 对于纵向GWAS,采用了可变系数复行混合模型关联测试 (RVMMAT).
- 分析了纵向损伤状态和粉样蛋白PET SUVR测量,并进行了后期途径和复制分析.
主要成果:
- 确定了244个全基因组显著的SNP,对临床损伤的时间影响有所不同,在70-80岁之间达到顶峰.
- 发现了73个全基因组显著的SNP,与粉样蛋白积累的时间变化有关,随着年龄的增长而增加影响.
- 途径分析揭示了重要的SNP涉及免疫反应和AD中的神经炎症途径.
结论:
- 具有时间变化的系数的纵向GWAS模型增强了AD遗传研究的统计能力.
- 发现了影响纵向临床和生物AD表型的新型时间变化的遗传变异.
- 为剖析AD等复杂疾病的动态遗传结构提供了一种强大的方法.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.2K
相关概念视频
Genome-wide Association Studies-GWAS
13.5K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.5K
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
